| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-06-16 | cathepsin S inhibitors including MIV-247 | neuropathic pain | preclinical | Medivir (Sweden) | CNS diseases |
| 2015-06-16 | JVS-100 | advanced ischemic chronic heart failure in patients with a prior history of heart attack |
2b | Juventas Therapeutics (USA - OH) | Cardiovascular diseases |
| 2015-06-16 | sembragiline (RG1577, EVT302) | Alzheimer\'s disease | 2a | Roche (Switzerland) | Neurodegenerative diseases |
| 2015-06-16 | ricolinostat (ACY-1215) in combination with Pomalyst® (pomalidomide) and dexamethasone | relapsed and refractory multiple myeloma |
1-2 | Acetylon Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2015-06-15 | immune checkpoint antibodies | preclinical | Tikcro Technologies (Israel) | Cancer - Oncology | |
| 2015-06-15 | olipudase alfa | acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease type B | 1-2 | Genzyme (USA - MA), a Sanofi company (France) | Rare diseases - Genetic diseases |
| 2015-06-15 | AVA-101 | wet age-related macular degeneration (wet AMD) |
2a | Avalanche Biotechnologies (USA - CA) | Ophtalmological diseases |
| 2015-06-15 | Combination Pan-Antigen Cytotoxic Therapy (ComPACT - Combination Immunotherapy Platform) | Heat Biologics (USA - NC) | Cancer - Oncology | ||
| 2015-06-15 | RPL554 | asthma | 2a | Verona Pharma (UK) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2015-06-15 | tosedostat | acute myeloid leukemia high risk myelodysplastic syndrome |
2 | CTI BioPharma - previously known as Cell Therapeutics (USA) National Cancer Research Institute (UK) | Cancer - Oncology |
| 2015-06-15 | SER150 | diabetic nephropathy | 2a | Serodus (Norway) | Metabolic diseases - Renal diseases - Kidney diseases |
| 2015-06-15 | BL-8040 | mobilization of stem cells from the bone marrow | 1 | BioLineRx (Israel) | Cancer - Oncology |
| 2015-06-12 | HT-100 (delayed-release halofuginone) | Duchenne muscular dystrophy (DMD) |
1b - 2a | Akashi Therapeutics (USA - MA) | Genetic diseases - Neuromuscular diseases - Rare diseases |
| 2015-06-12 | NEOD001 | AL amyloidosis or primary amyloidosis |
1-2 | Prothena (Ireland) | Rare diseases |
| 2015-06-12 | ofatumumab (Arzerra®) | chronic lymphocytic leukemia | 3 | Novartis (Switzerland) Genmab (Denmark) | Cancer - Oncology |
| 2015-06-12 | AG-348 | pyruvate kinase deficiency | 1 | Agios Pharmaceuticals (USA -MA) | Rare diseases - Genetic diseases |
| 2015-06-11 | ISIS-SMNRx (antisense oligonucleotide targeted to the SMN2 gene) | spinal muscular atrophy (SMA) | 2 | Isis Pharmaceuticals (USA - CA), now Ionis Pharmaceuticals (USA - CA) | Neuromuscular diseases - Rare diseases - Genetic diseases |
| 2015-06-11 | anti-citrullinated protein antibodies (tACPA) | rheumatoid arthritis |
preclinical | ModiQuest (The Netherlands) Citryll (The Netherlands) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-06-11 | tivozanib (N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N´-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate) | colorectal cancer (CRC) | 3 | Aveo Oncology (USA - MA) | Cancer - Oncology |
| 2015-06-11 | Cosentyx® - secukinumab (AIN457) | nail psoriasis | 3 | Novartis (Switzerland) | Autoimmune diseases - Dermatological diseases |
